ArticleAsia-Pacific journal of clinical oncology2025
Decoding the Role of CDCA Genes in Breast Cancer Progression: Insights From in Silico and Functional Assay.
Article in Asia-Pacific journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Role of cadherin gene dysregulation in WNT signaling and nasopharyngeal carcinoma.Cell division · 2026Article
- Decoding the Role of CDCA Genes in Breast Cancer Progression: Insights From in Silico and Functional Assay.Asia-Pacific journal of clinical oncology · 2025Article
- Role of cell division cycle associated 2 in ovarian cancer: Effects on tumor progression and cisplatin resistance.CytoJournal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe cell division cycle-associated (CDCA) genes regulate key cellular processes like cell cycle progression and division. This study evaluates the diagnostic and clinical relevance of CDCA genes in breast cancer. METHODOLOGY: Breast cancer and normal breast cell lines were cultured and analyzed for CDCA gene expression using RT-qPCR and further validated using public databases. Functional assays, including cell proliferation, colony formation, and wound healing, were performed following siRNA-mediated knockdown of CDCA2 and CDCA3. Mutational, CNV, methylation, and survival analyses, along with miRNA regulation and PPI network construction, were conducted to explore the role of CDCA genes in breast cancer progression.
resultsOur findings revealed significant upregulation of CDCA genes in breast cancer cell lines compared to normal controls, with all these genes exhibiting the highest diagnostic potential based on AUC values in ROC analysis. Pathological stage analysis indicated that CDCA5 and CDCA7 expression significantly varied across different breast cancer stages. Mutational analysis showed that CDCA2 had the highest mutation rate, with missense mutations being the most common. CNV analysis revealed amplification events in several CDCA genes, particularly CDCA2, CDCA3, CDCA4, and CDCA7. Promoter methylation analysis revealed significant hypomethylation in the CDCA genes in breast cancer, which correlated negatively with their expression. Survival analysis demonstrated that high expression of CDCA2, CDCA3, CDCA4, CDCA5, CDCA7, and CDCA8 was associated with worse overall survival, highlighting their prognostic significance. Furthermore, immune infiltration analysis revealed significant correlations between CDCA gene expression and immune cell types, suggesting a role in immune modulation. miRNA analysis identified specific miRNAs targeting CDCA genes, with several showing potential as diagnostic biomarkers. Lastly, the knockdown of CDCA2 and CDCA3 in breast cancer cells significantly reduced cell proliferation, colony formation, and migration, indicating their critical roles in tumor growth and metastasis.
conclusionThis study highlights CDCA genes as promising diagnostic and prognostic biomarkers in breast cancer. Their upregulation correlates with poor survival, and the knockdown of CDCA2 and CDCA3 impairs tumor growth, emphasizing their potential as therapeutic targets. These findings suggest that CDCA genes could be integrated into clinical practice for improved breast cancer management. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.